252 related articles for article (PubMed ID: 29129028)
1. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
Bandini M; Pompe RS; Marchioni M; Zaffuto E; Gandaglia G; Fossati N; Cindolo L; Montorsi F; Briganti A; Saad F; Karakiewicz PI
Int Urol Nephrol; 2018 Jan; 50(1):71-78. PubMed ID: 29129028
[TBL] [Abstract][Full Text] [Related]
2. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
[TBL] [Abstract][Full Text] [Related]
4. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
5. Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Prostate; 2021 Dec; 81(16):1374-1381. PubMed ID: 34523162
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis.
Antwi S; Everson TM
Cancer Epidemiol; 2014 Aug; 38(4):435-41. PubMed ID: 24802851
[TBL] [Abstract][Full Text] [Related]
9. Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
Wenzel M; Collà Ruvolo C; Würnschimmel C; Nocera L; Tian Z; Saad F; Briganti A; Tilki D; Graefen M; Becker A; Roos F; Mandel P; Chun FKH; Karakiewicz PI
Prostate; 2022 Jan; 82(1):78-85. PubMed ID: 34633102
[TBL] [Abstract][Full Text] [Related]
10. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
11. Real-world progression in the survival of de novo Metastatic prostate cancer over the past decade.
Guo X; Xia H; Zhang F; Hao G
Urol Oncol; 2024 Mar; 42(3):68.e1-68.e9. PubMed ID: 38097476
[TBL] [Abstract][Full Text] [Related]
12. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
[TBL] [Abstract][Full Text] [Related]
13. How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
Jin K; Qiu S; Li J; Zheng X; Tu X; Liao X; Yang Y; Yang L; Wei Q
Cancer Med; 2019 Jul; 8(7):3370-3378. PubMed ID: 31066510
[TBL] [Abstract][Full Text] [Related]
14. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
15. Improved survival for patients with de novo metastatic prostate cancer in the last 20 years.
Berg KD; Thomsen FB; Mikkelsen MK; Ingimarsdóttir IJ; Hansen RB; Kejs AM; Brasso K
Eur J Cancer; 2017 Feb; 72():20-27. PubMed ID: 28024263
[TBL] [Abstract][Full Text] [Related]
16. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
Sheng W; Zhang H; Lu Y
Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
[TBL] [Abstract][Full Text] [Related]
18. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
Ali A; Hoyle A; Mistry H; Clarke NW
BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
[TBL] [Abstract][Full Text] [Related]
19. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
20. Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?
Wu T; Zhao J; Liu Z; Shen P; Zhang M; Sun G; Liu J; Liao B; Chen J; Zhu S; Dai J; Wang Z; Zhang H; Zhao P; Zhang X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Oct; 79(14):1673-1682. PubMed ID: 31433509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
